A single centre experience of patients with rare cancers referred for early phase clinical trials
Participation of patients with rare cancers in EPCTs may be associated with a survival benefit and lead to the development of new treatments for these patients. Moreover, expanded use of precision medicine is paramount as it can inform targeted treatment selection in this heterogenous group.
Authors
- Fiona Thistlethwaite (ORCID: https://orcid.org/0000-0002-4832-7008)
- Donna M. Graham (ORCID: https://orcid.org/0000-0001-6500-8140)
- Louise Carter (ORCID: https://orcid.org/0000-0002-9854-2304)
- Natalie Cook (ORCID: https://orcid.org/0000-0003-2606-1082)
- Angelos Angelakas (ORCID: https://orcid.org/0000-0002-9769-9940)
- Matthew Krebs (ORCID: https://orcid.org/0000-0001-7540-3064)
Institutions
- University of Manchester (GB)
- The Christie NHS Foundation Trust (GB)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1186/s12885-025-13934-2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00